Author Identifier
Steve Pedrini
https://orcid.org/0000-0002-6409-8022
James Doecke
https://orcid.org/0000-0003-2863-0293
Eugene Hone
https://orcid.org/0000-0001-6708-3718
Rohith Thota
https://orcid.org/0000-0002-0293-913X
Ashley I. Bush
https://orcid.org/0000-0001-8259-9069
Christopher Rowe
https://orcid.org/0000-0003-3910-2453
Vincent Dore
https://orcid.org/0000-0002-8051-0558
Victor Villemagne
https://orcid.org/0000-0002-5832-9875
Stephanie Rainey-Smith
https://orcid.org/0000-0001-7328-9624
Giuseppe Verdile
https://orcid.org/0000-0003-2475-0124
Hamid Reza Sohrabi
https://orcid.org/0000-0001-8017-8682
Kevin Taddei
https://orcid.org/0000-0002-8106-7957
Colin L Masters
https://orcid.org/0000-0003-3072-7940
Pratishtha Chatterjee
https://orcid.org/0000-0003-4877-1958
Ralph Martins
Document Type
Journal Article
Publication Title
Journal of Neurochemistry
Publisher
Wiley
School
School of Medical and Health Sciences
RAS ID
52171
Funders
Cooperative Research Centre for Mental Health
National Health and Medical Research Council
Research Foundation
Victorian Government
Dementia Collaborative Research Centres
Science and Industry Endowment Fund
University of Melbourne
Edith Cowan University
Grant Number
NHMRC Number : GNT1197315
Abstract
Cholesterol levels have been repeatedly linked to Alzheimer's Disease (AD), suggesting that high levels could be detrimental, but this effect is likely attributed to Low-Density Lipoprotein (LDL) cholesterol. On the other hand, High-Density Lipoproteins (HDL) cholesterol levels have been associated with reduced brain amyloidosis and improved cognitive function. However, recent findings have suggested that HDL-functionality, which depends upon the HDL-cargo proteins associated with HDL, rather than HDL levels, appears to be the key factor, suggesting a quality over quantity status. In this report, we have assessed the HDL-cargo (Cholesterol, ApoA-I, ApoA-II, ApoC-I, ApoC-III, ApoD, ApoE, ApoH, ApoJ, CRP, and SAA) in stable healthy control (HC), healthy controls who will convert to MCI/AD (HC-Conv) and AD patients (AD). Compared to HC we observed an increased cholesterol/ApoA-I ratio in AD and HC-Conv, as well as an increased ApoD/ApoA-I ratio and a decreased ApoA-II/ApoA-I ratio in AD. Higher cholesterol/ApoA-I ratio was also associated with lower cortical grey matter volume and higher ventricular volume, while higher ApoA-II/ApoA-I and ApoJ/ApoA-I ratios were associated with greater cortical grey matter volume (and for ApoA-II also with greater hippocampal volume) and smaller ventricular volume. Additionally, in a clinical status-independent manner, the ApoE/ApoA-I ratio was significantly lower in APOE ε4 carriers and lowest in APOE ε4 homozygous. Together, these data indicate that in AD patients the composition of HDL is altered, which may affect HDL functionality, and such changes are associated with altered regional brain volumetric data.
DOI
10.1111/jnc.15681
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Comments
Pedrini, S., Doecke, J. D., Hone, E., Wang, P., Thota, R., Bush, A. I., ... & AIBL Research Group. (2022). Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume. Journal of Neurochemistry, 163(1), 53-67.
https://doi.org/10.1111/jnc.15681